ADMA Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of 95.19% compared to ADMA Biologics's net margin of 16.72%. ADMA Biologics's return on equity of 93.41% beat Biomarin Pharmaceutical's return on equity of 8.09%.

ADMA Biologics has a consensus price target of $25.27, signalling upside risk potential of 19.04%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.87 which suggests that it could grow by 64.69%. Given that Biomarin Pharmaceutical has higher upside potential than ADMA Biologics, analysts believe Biomarin Pharmaceutical is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.527, which suggesting that the stock is 47.277% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.302, suggesting its less volatile than the S&P 500 by 69.812%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $117.5M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. ADMA Biologics's net income of $111.9M is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, ADMA Biologics's price-to-earnings ratio is 25.89x while Biomarin Pharmaceutical's PE ratio is 26.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 12.09x versus 4.09x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of 95.19% compared to ADMA Biologics's net margin of 39.44%. ADMA Biologics's return on equity of 93.41% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

ADMA Biologics has a consensus price target of $25.27, signalling upside risk potential of 19.04%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $33.88 which suggests that it could grow by 52.66%. Given that Catalyst Pharmaceuticals has higher upside potential than ADMA Biologics, analysts believe Catalyst Pharmaceuticals is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.527, which suggesting that the stock is 47.277% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.371%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $117.5M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.8M. ADMA Biologics's net income of $111.9M is higher than Catalyst Pharmaceuticals's net income of $55.9M. Notably, ADMA Biologics's price-to-earnings ratio is 25.89x while Catalyst Pharmaceuticals's PE ratio is 16.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 12.09x versus 5.64x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Emergent BioSolutions has a net margin of 95.19% compared to ADMA Biologics's net margin of -16.54%. ADMA Biologics's return on equity of 93.41% beat Emergent BioSolutions's return on equity of -35.42%.

ADMA Biologics has a consensus price target of $25.27, signalling upside risk potential of 19.04%. On the other hand Emergent BioSolutions has an analysts' consensus of $13.50 which suggests that it could grow by 192.21%. Given that Emergent BioSolutions has higher upside potential than ADMA Biologics, analysts believe Emergent BioSolutions is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.527, which suggesting that the stock is 47.277% less volatile than S&P 500. In comparison Emergent BioSolutions has a beta of 2.141, suggesting its more volatile than the S&P 500 by 114.124%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Emergent BioSolutions pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $117.5M, which are smaller than Emergent BioSolutions quarterly revenues of $189.3M. ADMA Biologics's net income of $111.9M is higher than Emergent BioSolutions's net income of -$31.3M. Notably, ADMA Biologics's price-to-earnings ratio is 25.89x while Emergent BioSolutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 12.09x versus 0.24x for Emergent BioSolutions. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of 95.19% compared to ADMA Biologics's net margin of 21.57%. ADMA Biologics's return on equity of 93.41% beat TG Therapeutics's return on equity of 12.81%.

ADMA Biologics has a consensus price target of $25.27, signalling upside risk potential of 19.04%. On the other hand TG Therapeutics has an analysts' consensus of $43.00 which suggests that it could grow by 12.54%. Given that ADMA Biologics has higher upside potential than TG Therapeutics, analysts believe ADMA Biologics is more attractive than TG Therapeutics.

ADMA Biologics has a beta of 0.527, which suggesting that the stock is 47.277% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.139, suggesting its more volatile than the S&P 500 by 113.867%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $117.5M, which are larger than TG Therapeutics quarterly revenues of $108.2M. ADMA Biologics's net income of $111.9M is higher than TG Therapeutics's net income of $23.3M. Notably, ADMA Biologics's price-to-earnings ratio is 25.89x while TG Therapeutics's PE ratio is 272.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 12.09x versus 18.19x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.